Salmeterol and ciclesonide combination

• US 20060293293A1
• Filed: 05/19/2004
• Published: 12/28/2006
• Est. Priority Date: 05/22/2003
• Status: Abandoned Application

• Current Assignee: Nycomed GmbH (Takeda Pharmaceutical Company Limited)
• Original Assignee: Altana Pharma AG (Takeda Pharmaceutical Company Limited)
• Inventors: Shah, Tushar P., Muller, Helgert
• Application Number:
  US10/556,863
• Publication Number:
  US 20060293293A1
• Time in Patent Office: Days
• US Class Current: 514/171
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/452 Piperidinium derivatives pancuronium A61K31/58
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to pharmaceutical compositions containing combinations of salmeterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease.

Claims

1. A pharmaceutical composition comprising ciclesonide or a pharmaceutically acceptable salt or solvate thereof or a physiologically functional derivative of ciclesonide or solvate thereof and salmeterol or a pharmaceutically acceptable salt or solvate thereof or a physiologically functional derivative of salmeterol or solvate thereof, and a pharmaceutically acceptable carrier and/or one or more excipients, and optionally one or more other therapeutic ingredients.

2. The composition according to claim 1, wherein ciclesonide and salmeterol are contained in the same pharmaceutical formulation.

3. The composition according to claim 1, wherein the salmeterol is salmeterol xinafoate.

4. The composition according to claim 1, wherein the salmeterol is optically pure (S)-salmeterol.

5. The composition according to claim 1, comprising ciclesonide and salmeterol in an amount and ratio to be effective for a twice or once daily treatment of a clinical condition in a mammal for which a selective β

₂-adrenoreceptor agonist and/or glucocorticosteroid is indicated.

6. The composition according to claim 1, additionally containing tiotropium bromide or solvates thereof.

7. The pharmaceutical composition according to claim 1, which is suitable for administration by inhalation.

11. The pharmaceutical composition according to claim 7, which is a dry powder and the carrier is lactose monohydrate.

17. A dry powder inhalation product comprising a pharmaceutical composition according to claim 7.

8. A pharmaceutical aerosol composition comprising particles of salmeterol in a therapeutically effective amount and a therapeutically effective amount of ciclesonide and a hydrofluorocarbon propellant, and a cosolvent in an amount effective to solubilize ciclesonide and optionally a surfactant.

9. The pharmaceutical composition according to claim 8, wherein the cosolvent is ethanol.

18. A pharmaceutical aerosol product comprising an aerosol vial equipped with a metering valve and containing an aerosol formulation suitable for oral or nasal inhalation comprising a pharmaceutical aerosol composition according to claim 8.

19. A pharmaceutical aerosol product comprising an aerosol vial equipped with a metering valve and containing an aerosol formulation suitable for oral or nasal inhalation comprising a pharmaceutical aerosol composition according to claim 9.

21. The pharmaceutical aerosol composition according to claim 8, wherein the hydrofluorocarbon propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and mixtures thereof.

10. A pharmaceutical aerosol composition comprising particles of salmeterol in a therapeutically effective amount and particles of ciclesonide in a therapeutically effective amount and a hydrofluorocarbon propellant, and 0.01 to 5% w/w based upon propellant of polar cosolvent and optionally a surfactant.

20. A pharmaceutical aerosol product comprising an aerosol vial equipped with a metering valve and containing an aerosol formulation suitable for oral or nasal inhalation comprising a pharmaceutical aerosol composition according to claim 10.

22. The pharmaceutical aerosol composition according to claim 10, wherein the hydrofluorocarbon propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and mixtures thereof.

12. A method for the treatment of a clinical condition in a mammal for which a selective β

₂-adrenoreceptor agonist and/or glucocorticosteroid is indicated, which comprises administering a therapeutically effective amount of a pharmaceutical formulation comprising salmeterol or a pharmaceutical acceptable salt or solvate thereof, or a physiologically functional derivative of salmeterol or a solvate thereof, and ciclesonide or a pharmaceutical acceptable salt or solvate thereof, or a physiologically functional derivative of ciclesonide or a solvate thereof, and a pharmaceutical acceptable carrier and/or one or more excipients.

13. The method according to claim 12, wherein the clinical condition is selected from the group consisting of asthma, nocturnal asthma, exercise-induced asthma, chronic obstructive pulmonary diseases (COPD), chronic and wheezy bronchitis, emphysema, respiratory tract infection, upper respiratory tract disease, rhinitis, allergic rhinitis and seasonal rhinitis.

14. The method according to claim 12, which comprises a twice daily dosage regimen.

15. The method according to claim 12, which comprises a once daily dosage regimen.

16. The method according to claim 12, which comprises administering a combination of the ciclesonide and salmeterol in the same administration form by inhalation from an inhaler and wherein each actuation provides a dose therapeutically effective for a twice daily dosing regimen or for a once daily dosing regimen.